Full-Time

Director/Senior Director

Biostatistics

Confirmed live in the last 24 hours

Tango Therapeutics

Tango Therapeutics

51-200 employees

Develops targeted cancer therapies using synthetic lethality

Biotechnology
Healthcare

Senior

Boston, MA, USA

Office located at 201 Brookline Avenue, Fenway area of Boston, Massachusetts.

Category
Computational Biology
Public Health
Biology & Biotech
Required Skills
R
Data Analysis
Requirements
  • PhD in statistics or related discipline; MS with appropriate years of directly relevant experience
  • At least 8 years’ experience in the pharmaceutical or biotech industry
  • Experience in oncology required
  • Experience in the design, analysis, and reporting of clinical trials
  • Experience in INDs, NDAs, MAAs, or other regulatory submissions
  • In-depth knowledge of statistical methods for clinical trials
  • Knowledge of FDA, EMA, and ICH regulations and guidelines
  • Proficient in statistical programming (SAS and R)
  • Ability to lead statistical efforts for multiple studies
  • Fluent in data standards, including SDTM and ADaM
  • Experience in outsourced statistical services provided by CROs
  • Ability to work independently and act with initiative to address issues
  • Excellent written and oral communication skills, including the ability to effectively communicate statistical concepts in a clear and concise manner
Responsibilities
  • Serve as a biostatistics expert for Tango’s clinical programs
  • Provide strategic input to optimize trial designs in early phase dose escalation studies and late phase registrational studies
  • As a biostatistics representative, proactively collaborate with internal and external CRO team members to coordinate the planning and execution of statistical deliverables
  • Conduct statistical modeling to enable robust and efficient statistical designs and address identified or potential statistical issues arising with studies
  • Contribute to clinical protocol development, including authoring or review of the Statistics section and reviewing of other sections by applying statistical principles
  • Author or review the development of statistical analysis plans for clinical trials and oversee the development of tables, figures, and listings, and associated deliverables
  • Review electronic case report form (eCRF) designs to ensure data collection meets the requirements of statistical analyses
  • Provide statistical input for clinical documents
  • Perform QC/QA of statistical deliverables including validation of key analysis results
  • Perform ad hoc statistical analyses as needed
  • Contribute to clinical study reports, including authoring of statistical methods, and interpretation of study results
  • Accountable for assigned statistical activities in support of IND/NDA/MAA or other regulatory submissions; provide thorough review for required components of regulatory submissions including appropriate datasets, define files, reviewer's guides, and other relevant documents
  • Address statistical questions/comments from FDA and other regulatory agencies, or IRB/ECs
  • Support and contribute to the preparation of publications, including manuscripts, posters, and oral presentations
  • Lead standardization and process improvement efforts for Biostatistics function, and contribute to cross-functional process improvement efforts including the definition of biostatics templates and standards
  • Represent Tango regarding statistical issues in meetings with external parties including regulatory agencies and corporate partners
  • Support inspection readiness activities as needed
  • Develop and maintain advanced competencies in statistical methodology and advanced trial designs, particularly in oncology drug development
  • Additional duties and responsibilities as required

Tango Therapeutics develops targeted cancer treatments using the principle of synthetic lethality, which allows them to design drugs that kill cancer cells while leaving healthy cells unharmed. Their approach focuses on the interaction between genes, where the loss of both genes leads to cell death, but the loss of just one does not. This method enables them to create more effective therapies for cancer patients. Tango operates in the oncology market, primarily serving healthcare providers and pharmaceutical companies. They collaborate with larger firms, like Gilead Sciences, to co-develop therapies, which helps them secure funding and speed up the development process. Their goal is to bring next-generation targeted immunotherapies to market, supported by a strong team and strategic partnerships.

Company Stage

N/A

Total Funding

$341.4M

Headquarters

Cambridge, Massachusetts

Founded

2017

Growth & Insights
Headcount

6 month growth

5%

1 year growth

22%

2 year growth

90%
Simplify Jobs

Simplify's Take

What believers are saying

  • Tango's recent $80 million private placement financing strengthens their financial position and supports ongoing R&D efforts.
  • The company's ability to secure Orphan Drug Designation and Fast Track Designation for their therapies highlights their potential to bring innovative treatments to market quickly.
  • Participation in high-profile investor conferences and scientific meetings enhances Tango's visibility and credibility in the biotech community.

What critics are saying

  • The discontinuation of the TNG348 program due to liver toxicity raises concerns about the safety and viability of their drug candidates.
  • The highly competitive oncology market requires continuous innovation and successful clinical trials to maintain a leading position.

What makes Tango Therapeutics unique

  • Tango Therapeutics leverages the principle of synthetic lethality to develop cancer treatments, a unique approach that specifically targets cancer cells while sparing healthy ones.
  • Their strategic collaborations with larger pharmaceutical companies like Gilead Sciences provide financial support and accelerate the development and commercialization of their therapies.
  • Tango's robust pipeline and focus on precision oncology, including targeting MTAP-deleted solid tumors and BRCA1/2 mutations, set them apart in the oncology market.

Help us improve and share your feedback! Did you find this helpful?